Cirrhosis Registry of Hospitalized Patients

NCT ID: NCT04767945

Last Updated: 2022-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-01

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cirrhosis registry of consecutive adult consenting patients hospitalized with liver cirrhosis in the tertiary liver unit

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

On admission to F.D.Roosevelt Teaching Hospital / HEGITO Liver Unit (Div Hepatology, Gastroenterology and Liver Transplant), all the adult patients with liver cirrhosis are offered to participate.

After providing informed consent, their demographic, clinical and laboratory / imaging data are uploaded by dedicated study person After discharge from the hospital, follow-up is recommended and uploaded to RH7 (if the follow-up visits take place at this institution \[FDR\]) Mortality data are uploaded from the national registry of dead on regular basis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis, Liver Frailty Ascites Encephalopathy Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults with liver cirrhosis admitted to hospital liver unit

Consenting adults admitted with liver cirrhosis; recorded/uploaded are demographic, clinical, laboratory and imaging data

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* liver cirrhosis (primarily on clinical grounds)
* decompensating event leading to hospital admission
* informed consent

Exclusion Criteria

* declined consent
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ľubomír Skladaný MD, PhD

Head, Department of Internal Medicine and HEGITO Liver Unit, Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lubomir Skladany, MD PhD

Role: PRINCIPAL_INVESTIGATOR

F.D.Roosevelt Teaching Hospital, Banska Bystrica, Slovakia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

F.D.Roosevelt Teaching Hospital

Banská Bystrica, , Slovakia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Slovakia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lubomir Skladany, MD, PhD

Role: CONTACT

+421905482997

Janka Vnencakova, PhD

Role: CONTACT

+421902160743

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Lubomir Skladany, MD, PhD

Role: primary

+421905482997

Natalia Bystrianska, MD

Role: backup

+421917944393

References

Explore related publications, articles, or registry entries linked to this study.

Koller T, Vrbova P, Kubanek N, Zilincanova D, Selcanova SA, Havaj DJ, Skladany L. Assessment of intestinal inflammation via fecal calprotectin for early prediction of adverse outcomes in advanced chronic liver disease. United European Gastroenterol J. 2025 Apr;13(3):305-316. doi: 10.1002/ueg2.12633. Epub 2024 Jul 19.

Reference Type DERIVED
PMID: 39031494 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HEGITO2014

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Hepatic Excision and Ablation Log
NCT06870461 NOT_YET_RECRUITING
Nursing Needs of Patients With Cirrhosis
NCT07273331 ENROLLING_BY_INVITATION